Soluble Interleukin-2 Receptors in Cancer Patients
Author Information
Author(s): P. Lissoni, S. Barnil, R. Rescaldani, F. Rovelli, G. Tancini
Primary Institution: Hospital of Monza
Hypothesis
What is the relationship between serum levels of soluble interleukin-2 receptors and lymphocyte subpopulations in patients with metastatic solid tumors?
Conclusion
The study found that metastatic solid tumors are associated with increased levels of soluble interleukin-2 receptors, but these levels do not correlate with immune dysfunction markers.
Supporting Evidence
- 75% of metastatic patients had high serum levels of sIL-2R.
- Only 16.6% of non-metastatic patients had high sIL-2R levels.
- Metastatic patients had significantly higher sIL-2R levels compared to healthy controls.
- A reduced CD4/CD8 ratio was found in 53% of metastatic patients.
Takeaway
This study looked at blood levels of a protein called sIL-2R in cancer patients and found that those with advanced cancer had higher levels, but it didn't mean their immune system was weaker.
Methodology
The study measured serum levels of sIL-2R and lymphocyte subpopulations using blood samples from patients and healthy controls.
Limitations
The study did not establish a direct correlation between sIL-2R levels and immune dysfunction due to lack of significant correlation with CD4/CD8 ratio.
Participant Demographics
32 patients with metastatic solid tumors, median age 57 years, both sexes.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Want to read the original?
Access the complete publication on the publisher's website